Amneal Pharmaceuticals, Inc.
AMRX
Rankning i aktier
#3004
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Aktiekurs
$19.07
Senast synkroniserad: 2026-10-16
Marknadsvärde
$6.09B
Förändring (1 dag)
-0.94%
Förändring (1 år)
92.24%
Land
US
Handel Amneal Pharmaceuticals, Inc. (AMRX)
Kategori
Healthcare
Rörelsemarginal för Amneal Pharmaceuticals, Inc. (AMRX)
Rörelsemarginal per October 2026 TTM: 12.93%
Enligt de senaste finansiella rapporterna och aktiekursen för Amneal Pharmaceuticals, Inc. är företagets nuvarande rörelsemarginal (TTM) 12.93%. Vid slutet av 2023 var rörelsemarginalen 8.54%.
Historik för rörelsemarginal för Amneal Pharmaceuticals, Inc. från 2014 till 2026
Rörelsemarginal vid slutet av varje år
| År | Rörelsemarginal | Ändra |
|---|---|---|
| 2026 (TTM) | 12.93% | 44.96% |
| 2024 | 8.92% | 4.45% |
| 2023 | 8.54% | -299.07% |
| 2022 | -4.29% | -158.85% |
| 2021 | 7.29% | 59.52% |
| 2020 | 4.57% | -154.08% |
| 2019 | -8.45% | 616.10% |
| 2018 | -1.18% | -104.98% |
| 2017 | 23.71% | -15.26% |
| 2016 | 27.98% | 6.67% |
| 2015 | 26.23% | -7.58% |
| 2014 | 28.38% | 0.00% |
Rörelsemarginal för liknande företag eller konkurrenter
| Företag | Rörelsemarginal | Skillnad i rörelsemarginal | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -98.23% |
IN
|
Vad är ett företags Rörelsemarginal?
Rörelsemarginal är en viktig indikator för att bedöma ett företags lönsamhet. Högre Rörelsemarginals är generellt bättre eftersom de visar att ett företag kan sälja sina produkter eller tjänster för betydligt mer än produktionskostnaden. Rörelsemarginal beräknas genom att dividera företagets vinst med dess intäkter.